BIOR - Biora Therapeutics, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
San Diego,
United States
Type: Equity
BIOR price evolution
BIOR
| (in millions $) | 31 Jan 2024 | 30 Oct 2023 | 30 Jul 2023 | 1 May 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | $0.83 | $0.8 | $0.82 | $0.83 |
| Inventory | ||||
| Total current assets | $19.07 | $19.2 | $33.88 | $37.17 |
| Long term investments | ||||
| Property, plant & equipment | $2.77 | $3.1 | $3.24 | $3.74 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $31.21 | $34.7 | $49.67 | $53.24 |
| Current liabilities | ||||
| Accounts payable | $2.84 | $3.9 | $5.04 | $3.42 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $62.97 | $69.5 | $37.67 | $25.08 |
| Long term debt | $43.74 | $80.4 | $128.57 | $128.19 |
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $132.64 | $153.5 | $170.55 | $158.24 |
| Shareholders' equity | ||||
| Retained earnings | -$950.96 | -$935.5 | -$862.09 | -$844.28 |
| Other shareholder equity | ||||
| Total shareholder equity | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 31 Jan 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | $0.83 | $0.83 | $0.65 | $6.63 |
| Inventory | $12.22 | |||
| Total current assets | $19.07 | $38.12 | $98.43 | $126.34 |
| Long term investments | ||||
| Property, plant & equipment | $2.77 | $3.14 | $4.01 | $8.11 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $31.21 | $53.52 | $108.84 | $154.44 |
| Current liabilities | ||||
| Accounts payable | $2.84 | $3.61 | $8.71 | $17.38 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $62.97 | $23.3 | $61.61 | $72.67 |
| Long term debt | $43.74 | $127.81 | $126.39 | $160.2 |
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $132.64 | $155.81 | $193.81 | $261.43 |
| Shareholders' equity | ||||
| Retained earnings | -$950.96 | -$826.84 | -$788.69 | -$541.27 |
| Other shareholder equity | ||||
| Total shareholder equity | ||||
| (in millions $) | 30 Oct 2022 | 30 Jul 2022 | 30 Apr 2022 | 31 Jan 2022 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $0.08 | $0.11 | $0.43 | |
| Cost of revenue | ||||
| Gross Profit | $0.43 | |||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $13.97 | $20.02 | $20.59 | |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | $0.16 | -$0.12 | ||
| Interest expense | -$0.73 | $6.23 | -$50.52 | |
| Net income | ||||
| Net income | -$5.11 | -$13.81 | -$92.87 | |
| Income (for common shares) | ||||
| (in millions $) | 31 Jan 2022 | 31 Jan 2021 | 31 Jan 2020 | 31 Jan 2019 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $1.25 | $0.16 | $143.99 | $127.97 |
| Cost of revenue | ||||
| Gross Profit | $1.25 | $0.16 | $43.49 | $35.9 |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $119.08 | $107.78 | $183.61 | $150.13 |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | -$0.12 | -$37.53 | -$0.71 | $5.25 |
| Interest expense | -$66.79 | -$9.91 | -$9.2 | -$11.42 |
| Net income | ||||
| Net income | -$247.41 | -$192.53 | -$148.04 | -$129.11 |
| Income (for common shares) | ||||
| (in millions $) | 30 Oct 2022 | 30 Jul 2022 | 30 Apr 2022 | 31 Jan 2022 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$0.72 | -$0.56 | -$0.34 | -$1.24 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $2.78 | $4.26 | $3.13 | $165.05 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$51.34 | -$39.89 | -$21.16 | -$3.68 |
| (in millions $) | 31 Jan 2022 | 31 Jan 2021 | 31 Jan 2020 | 31 Jan 2019 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$1.24 | -$4.94 | $16.52 | $55.83 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $165.05 | $229.72 | $73.64 | -$12.81 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$3.68 | $59.04 | -$15.96 | -$22.11 |
News
Fundamentals
| Market cap | $15.15M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 23.70M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | -55.56% |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 0.30 |
| Quick ratio | N/A |